Effect of glucocorticoid use on survival in patients with stage I–III breast cancer
- 14 May 2018
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 171 (1) , 225-234
Abstract
Glucocorticoids (GCs) are commonly used in breast cancer patients to ameliorate emesis induced by chemotherapy. Some preclinical studies have suggested that systemic GCs might promote survival of estrogen receptor (ER)-negative breast cancer cells. This study aims to clarify their clinical effect on patient survival.Keywords
Funding Information
- National Science Council (NSC 99-2410-H-038-004)
- National Center of Excellence for Clinical Trial and Research (MOHW105-TDU-B-211-134005)
- Ministry of Science and Technology, Taiwan (MOST 105-2911-I-002-302)
This publication has 33 references indexed in Scilit:
- Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancerNature Communications, 2015
- Association Between Nucleoside Analogues and Risk of Hepatitis B Virus–Related Hepatocellular Carcinoma Recurrence Following Liver ResectionJAMA, 2012
- In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survivalThe Journal of Pathology, 2011
- Effects of corticosteroid use on treatment of solid tumoursThe Lancet, 2002
- A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancerBritish Journal of Cancer, 1994
- A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the north central cancer treatment group and mayo clinicCancer, 1991
- Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An eastern cooperative oncology group trialCancer, 1990
- Prednisolone improves the response to primary endocrine treatment for advanced breast cancerBritish Journal of Cancer, 1988
- Medroxyprogesterone acetate and prednisone in advanced breast cancer. A randomized trialEuropean Journal of Cancer and Clinical Oncology, 1986
- Contribution of prednisolone to the primary endocrine treatment of advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1982